Status:
UNKNOWN
Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
Lead Sponsor:
Oregon Health and Science University
Conditions:
Liver Transplantation
Eligibility:
All Genders
18-80 years
Brief Summary
Null Hypothesis: There is no significant difference in the incidence of CMV infection when using oral valganciclovir or ganciclovir as prophylactic anti-viral therapy. Alternate Hypothesis: There e...
Detailed Description
The objective for this retrospective clinical study is to describe the incidence of CMV infection in orthoptic liver transplant recipients who receive oral valganciclovir or ganciclovir as their CMV p...
Eligibility Criteria
Inclusion
- All liver transplants will be performed at Oregon Health \& Science University (OHSU) and the OHSU surgical and medical staff will treat patients.
Exclusion
- Portland Veterans Affairs Medical Center liver transplant recipients
- Patients deceased within thirty days of receiving liver allograft
- Patients with low risk of acquiring CMV infection: donor-negative and recipient-negative (D-/R-)
- Patients undergoing re-transplantation
- Lost to follow-up (minimum follow-up is 1 year)
- History of CMV infection or disease
- Anti-CMV therapy within the past 30 d
- Severe, uncontrolled diarrhea or evidence of malabsorption.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
OBSERVATIONAL
End Date :
January 1 2007
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00364052
Start Date
August 1 2006
End Date
January 1 2007
Last Update
August 17 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.